Vericel Corp (NASDAQ:VCEL) COO Michael Halpin sold 15,047 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $18.53, for a total value of $278,820.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of VCEL opened at $18.54 on Friday. The business’s fifty day simple moving average is $15.80 and its two-hundred day simple moving average is $16.93. The company has a current ratio of 6.93, a quick ratio of 6.48 and a debt-to-equity ratio of 0.26. Vericel Corp has a 12 month low of $13.40 and a 12 month high of $21.00. The company has a market cap of $858.36 million, a price-to-earnings ratio of -132.43 and a beta of 2.66.
Vericel (NASDAQ:VCEL) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.09. Vericel had a positive return on equity of 3.66% and a negative net margin of 12.68%. The business had revenue of $30.50 million for the quarter, compared to the consensus estimate of $26.84 million. During the same period last year, the business posted ($0.02) EPS. The company’s revenue was up 35.6% compared to the same quarter last year. As a group, research analysts forecast that Vericel Corp will post 0.16 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of VCEL. Waddell & Reed Financial Inc. purchased a new stake in Vericel during the 2nd quarter valued at $38,159,000. Nuveen Asset Management LLC purchased a new stake in Vericel during the 2nd quarter valued at $16,152,000. Redwood Investments LLC purchased a new stake in Vericel during the 2nd quarter valued at $15,775,000. SG Capital Management LLC purchased a new stake in Vericel during the 2nd quarter valued at $12,907,000. Finally, Fort Washington Investment Advisors Inc. OH purchased a new position in shares of Vericel in the 2nd quarter worth $11,655,000. Institutional investors and hedge funds own 88.18% of the company’s stock.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
Further Reading: Analyzing a company’s cash flow statement
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.